arrow
M

Mark M. Awad

massachusetts general hospital
H指数:86
被引数:3.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Kras G12C– and G12D–driven lung cancers differ in oncogenic potency; immunogenicity; and relapse after Kras inhibition in mouse models

Kras G12C-和G12D-driven肺癌在致瘤能力、免疫原性和小鼠模型中Kras抑制后的复发方面不同

2026-02-040
PRE
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis

III期可切除NSCLC患者围手术期nivolumab的临床结局: CheckMate 77t 3期探索性分析

2026-01-080
OAAI
Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC A Multicenter Retrospective Study

继续使用下一代ALK TKIs联合化疗治疗晚期ALK阳性NSCLC的疗效与安全性:一项多中心回顾性研究

2025-12-010
PRE
Clinical Significance of MTAP Deletions and their Overlap with Concurrent Oncogenic Driver Alterations Including EGFR in Non-Small Cell Lung Cancer

MTAP缺失的临床意义及其与非小细胞肺癌中包括EGFR在内的并发致癌驱动基因改变的重叠情况

2025-11-170
PRE
CRATER tumor niches facilitate CD8+ T cell engagement and correspond with immunotherapy success

CRATER肿瘤微环境促进CD8+ T细胞浸润,并与免疫治疗效果相关

Cell
IF42.5
2025-10-170
OAAI
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

晚期非小细胞肺癌患者接受双重CTLA-4和PD-L1或PD-1阻断治疗及生物标志物基础亚组分析的长期总生存:一项系统评价和重建个体患者数据荟萃分析

2025-09-290
PRE
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers with Different MET Exon 14 Skipping Mutations.

简报:DNA测序在区分具有不同MET外显子14跳跃突变的不同原发性肺癌中的关键作用。

2025-09-200
PRE
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival

非小细胞肺癌患者新辅助化免疫治疗的实际结果:手术、病理完全缓解和事件无进展生存的预测因素

Cancer
IF5.1
2025-09-090
PRE
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multi-Center Retrospective Study

肺肉瘤样癌的特定临床基因组学特征及与免疫治疗的相关性:一项多中心回顾性研究

2025-07-250
OAAI
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

机器学习驱动的转移性非小细胞肺癌免疫治疗适应性策略

2025-07-240
OAAI
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer

DNA甲基转移酶3A(DNMT3A)突变与非小细胞肺癌中PD-(L)1阻断疗法的疗效

2025-06-180
PRE
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

MET激酶域激活突变与其他驱动癌基因共发生,并介导非小细胞肺癌对靶向治疗的耐药性

2025-04-020
PRE
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung Cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients

老年非小细胞肺癌患者(≥80岁)的肿瘤免疫表型相关性及PD-L1高表达(≥50%)患者接受一线帕博利珠单抗治疗的结局

2025-02-040
PRE
Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC

STK11、KEAP1和SMARCA4基因拷贝数缺失:临床病理特征及其与免疫治疗联合或单独化疗在非鳞状NSCLC中疗效的关联

2025-01-270
PRE